Neuren Pharmaceuticals shares (ASX:NEU) delivered the standout performance on the ASX 200 today, rallying 16.28% to A$21.64 after reporting record second-quarter DAYBUE sales and significantly raising its full-year royalty income expectations, underscoring the commercial momentum behind its flagship rare-disease therapy.
The Neuren Pharma share price tested the A$22 resistance level intraday, marking one of the strongest single-session gains for the stock in recent months, coming as markets worked through a substantial beat on quarterly sales figures and upgraded financial guidance that points to accelerating demand for DAYBUE, the first approved treatment for Rett syndrome.
Driving The Rally In Neuren Pharma
Neuren’s US partner Acadia Pharmaceuticals reported second-quarter 2026 DAYBUE net sales of US$125 million, representing a 30% increase year-on-year and a 24% jump from the first quarter. The volume-driven growth translated directly into higher royalty income for Neuren, which recorded US$12.9 million in second-quarter royalties, up 34% from the prior-year period.
The strength of the quarterly performance prompted Acadia to raise its full-year 2026 DAYBUE net sales guidance to a range of US$480 million to US$510 million, up from the previous US$460 million to US$490 million band. Neuren subsequently upgraded its expected full-year royalty income to between US$53 million and US$56 million, providing a meaningful uplift to consensus earnings forecasts.
Top Australian Brokers
- Pepperstone - Top Australian broker - Read our review
- eToro - Invest in ASX and international shares - Read our review
A key driver behind the sales acceleration has been the rapid uptake of DAYBUE STIX, a newer powder formulation designed to improve ease of administration. By the end of the second quarter, approximately 40% of DAYBUE patients had adopted STIX, with around 45% of that demand coming from new or returning patients rather than simple switches from the liquid formulation. The data suggests the product innovation is expanding the addressable patient population and potentially improving treatment adherence, addressing a concern that has lingered among some market participants regarding long-term retention rates.
The positive commercial momentum in North America is complemented by significant regulatory progress in international markets. In June, the European Medicines Agency’s Committee for Medicinal Products for Human Use adopted a positive opinion for DAYBUE following a re-examination process. The recommendation now moves to the European Commission for final approval, which typically follows within a defined timeframe. If granted, DAYBUE would become the first therapy approved in the European Union specifically for the neurobehavioral symptoms of Rett syndrome in adults and children aged five years and older.
European approval carries material financial implications beyond the royalty stream. Neuren has indicated that a positive decision from the European Commission would trigger an upfront milestone payment of approximately US$35 million, providing non-dilutive capital to support ongoing operations and pipeline development. Management commentary suggests an initial commercial launch could occur in Germany as early as the fourth quarter of 2026, with subsequent rollout across other European markets.
In Japan, Neuren’s partner is progressing a pivotal trofinetide trial on schedule, with top-line results anticipated between September and November 2026. A regulatory submission is targeted for 2027, potentially opening a third major market for the therapy. Japan’s well-established reimbursement framework for rare-disease treatments makes it an attractive commercial opportunity, though the trial represents a binary clinical catalyst that carries execution risk.
The sequential acceleration in DAYBUE sales and the geographic expansion story have shifted market perceptions of Neuren from a speculative biotech to an increasingly predictable royalty-driven business model. The company’s capital-light structure means that incremental DAYBUE sales flow through to royalty income with minimal associated costs, improving operating leverage and cash generation. The strengthened balance sheet, bolstered by rising royalties and the pending European milestone, also provides greater flexibility to advance NNZ-2591, Neuren’s pipeline asset in neurodevelopmental disorders, without heavy equity dilution.
What Next For NEU?
From a technical perspective, the stock’s test of the A$22 level represents a key inflection point. A sustained break above that resistance could open the path toward the previous all-time highs, while failure to hold current gains may see a retracement toward the A$19 to A$20 support zone.
The fundamental case for Neuren Pharma shares has clearly strengthened, with visible execution across multiple fronts reinforcing confidence in the commercial trajectory. Yet the stock’s biotech risk profile and dependency on continued flawless execution mean that any stumble could compress the valuation multiple quickly.
Bull Case:
- Record Q2 sales and upgraded guidance demonstrate sustained, volume-driven demand growth
- DAYBUE STIX expanding patient base with 45% from new/returning users
- European approval imminent, unlocking US$35 million milestone and new royalty stream
- High-margin royalty model with minimal incremental costs improves operating leverage
- Japan pivotal trial on track for late-2026 data, adding third major market
Bear Case:
- Revenue entirely dependent on single product and commercialisation partner Acadia Pharmaceuticals
- Elevated expectations after sharp re-rating increase vulnerability to any execution missteps
- EU pricing and reimbursement negotiations may delay broad uptake beyond Germany
- Japan trial represents binary clinical risk with results not yet de-risked
- Any safety concerns or competitive entrants would disproportionately impact concentrated revenue base
